세계의 폐 약물 전달 시스템 시장 규모 조사 및 예측, 제품별, 용도별(천식, 만성 폐쇄성 폐질환, 낭포성 섬유증), 유통 채널별, 지역별 분석(2022-2029년)

Global Pulmonary Drug Delivery Systems Market is valued approximately USD 46613.07 million in 2021 and is anticipated to grow with a healthy growth rate of more than 6.80% over the forecast period 2022-2029. Pulmonary drug delivery systems are devices that are used to deliver medication directly to the lungs through inhalation. These devices are commonly used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Thus, the major driving factors for the Global Pulmonary Drug Delivery Systems Market are increasing prevalence of respiratory diseases, increasing healthcare expenditure and growing demand for personalized medicine. Moreover, technological advancements and government initiatives is creating lucrative growth opportunity for the market over the forecast period 2022-2029.

The US FDA has been working to encourage the development of new pulmonary drug delivery systems. In 2019, the FDA issued a guidance document for industry on the development of inhaled drug products. The document provides recommendations on the design of clinical trials, the use of in vitro testing methods, and other aspects of product development. Similarly, in 2020, the European Medicines Agency (EMA) issued a reflection paper on the development of inhalation products. The paper provides guidance to drug developers on issues such as product design, formulation, and clinical trial design. However, the high cost of Pulmonary Drug Delivery Systems stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Pulmonary Drug Delivery Systems Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is expected to hold the largest share of the pulmonary drug delivery systems market due to the high prevalence of respiratory diseases such as asthma and COPD in the region, as well as the presence of well-established healthcare infrastructure and high levels of healthcare expenditure. The Asia-Pacific region is expected to experience the fastest growth in the pulmonary drug delivery systems market, driven by factors such as increasing healthcare expenditure, rising disposable incomes, and increasing awareness of respiratory diseases. In addition, the region's large population and high burden of respiratory diseases are expected to contribute to market growth.

Major market players included in this report are:

• AstraZeneca plc
• Boehringer Ingelheim GmbH
• GlaxoSmithKline plc
• Novartis AG
• Koninklijke Philips N.V.
• 3M company
• Janssen (Johnson & Johnson)
• Clement Clarke International
• Briggs Healthcare
• Aerogen

Recent Developments in the Market:

• In 2019, AstraZeneca launched its Bevespi Aerosphere, a dual-bronchodilator inhaler, for the treatment of chronic obstructive pulmonary disease (COPD) in the US market. The company also collaborated with Breath Therapeutics in 2019 to develop inhaled therapies for patients with pulmonary disease.
• In 2020, GlaxoSmithKline received FDA approval for its Nucala autoinjector for the treatment of severe asthma. The company also announced a partnership with Verona Pharma in 2020 to develop a nebulized therapy for the treatment of respiratory diseases.

Global Pulmonary Drug Delivery Systems Market Report Scope:

• Historical Data: 2019-2020-2021
• Base Year for Estimation: 2021
• Forecast period: 2022-2029
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Product, Application, Distribution Channel, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Product:

• Dry Powder Inhaler
• Metered Dose Inhaler and Nebulizers

By Application:

• Asthma
• Chronic Obstructive Pulmonary Diseases (COPD)
• Cystic Fibrosis

By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• E-Commerce

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
  • 1.2.1. Pulmonary Drug Delivery Systems Market, by Region, 2019-2029 (USD Million)
  • 1.2.2. Pulmonary Drug Delivery Systems Market, by Product, 2019-2029 (USD Million)
  • 1.2.3. Pulmonary Drug Delivery Systems Market, by Application, 2019-2029 (USD Million)
  • 1.2.4. Pulmonary Drug Delivery Systems Market, by Distribution Channel, 2019-2029 (USD Million)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Pulmonary Drug Delivery Systems Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Pulmonary Drug Delivery Systems Market Dynamics

• 3.1. Pulmonary Drug Delivery Systems Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing prevalence of respiratory diseases
    • 3.1.1.2. Increasing healthcare expenditure
    • 3.1.1.3. Growing demand for personalized medicine
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Pulmonary Drug Delivery Systems
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Technological advancements
    • 3.1.3.2. Government initiatives

Chapter 4. Global Pulmonary Drug Delivery Systems Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Investment Adoption Model
• 4.5. Analyst Recommendation & Conclusion
• 4.6. Top investment opportunity
• 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Pulmonary Drug Delivery Systems Market, by Product

• 6.1. Market Snapshot
• 6.2. Global Pulmonary Drug Delivery Systems Market by Product, Performance - Potential Analysis
• 6.3. Global Pulmonary Drug Delivery Systems Market Estimates & Forecasts by Product 2019-2029 (USD Million)
• 6.4. Pulmonary Drug Delivery Systems Market, Sub Segment Analysis
  • 6.4.1. Dry Powder Inhaler
  • 6.4.2. Metered Dose Inhaler and Nebulizers

Chapter 7. Global Pulmonary Drug Delivery Systems Market, by Application

• 7.1. Market Snapshot
• 7.2. Global Pulmonary Drug Delivery Systems Market by Application, Performance - Potential Analysis
• 7.3. Global Pulmonary Drug Delivery Systems Market Estimates & Forecasts by Application 2019-2029 (USD Million)
• 7.4. Pulmonary Drug Delivery Systems Market, Sub Segment Analysis
  • 7.4.1. Asthma
  • 7.4.2. Chronic Obstructive Pulmonary Diseases (COPD)
  • 7.4.3. Cystic Fibrosis

Chapter 8. Global Pulmonary Drug Delivery Systems Market, by Distribution Channel

• 8.1. Market Snapshot
• 8.2. Global Pulmonary Drug Delivery Systems Market by Distribution Channel, Performance - Potential Analysis
• 8.3. Global Pulmonary Drug Delivery Systems Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Million)
• 8.4. Pulmonary Drug Delivery Systems Market, Sub Segment Analysis
  • 8.4.1. Retail Pharmacies
  • 8.4.2. Hospital Pharmacies
  • 8.4.3. E-Commerce

Chapter 9. Global Pulmonary Drug Delivery Systems Market, Regional Analysis

• 9.1. Pulmonary Drug Delivery Systems Market, Regional Market Snapshot
• 9.2. North America Pulmonary Drug Delivery Systems Market
  • 9.2.1. U.S. Pulmonary Drug Delivery Systems Market
    • 9.2.1.1. Product breakdown estimates & forecasts, 2019-2029
    • 9.2.1.2. Application breakdown estimates & forecasts, 2019-2029
    • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
  • 9.2.2. Canada Pulmonary Drug Delivery Systems Market
• 9.3. Europe Pulmonary Drug Delivery Systems Market Snapshot
  • 9.3.1. U.K. Pulmonary Drug Delivery Systems Market
  • 9.3.2. Germany Pulmonary Drug Delivery Systems Market
  • 9.3.3. France Pulmonary Drug Delivery Systems Market
  • 9.3.4. Spain Pulmonary Drug Delivery Systems Market
  • 9.3.5. Italy Pulmonary Drug Delivery Systems Market
  • 9.3.6. Rest of Europe Pulmonary Drug Delivery Systems Market
• 9.4. Asia-Pacific Pulmonary Drug Delivery Systems Market Snapshot
  • 9.4.1. China Pulmonary Drug Delivery Systems Market
  • 9.4.2. India Pulmonary Drug Delivery Systems Market
  • 9.4.3. Japan Pulmonary Drug Delivery Systems Market
  • 9.4.4. Australia Pulmonary Drug Delivery Systems Market
  • 9.4.5. South Korea Pulmonary Drug Delivery Systems Market
  • 9.4.6. Rest of Asia Pacific Pulmonary Drug Delivery Systems Market
• 9.5. Latin America Pulmonary Drug Delivery Systems Market Snapshot
  • 9.5.1. Brazil Pulmonary Drug Delivery Systems Market
  • 9.5.2. Mexico Pulmonary Drug Delivery Systems Market
• 9.6. Rest of The World Pulmonary Drug Delivery Systems Market

Chapter 10. Competitive Intelligence

• 10.1. Top Market Strategies
• 10.2. Company Profiles
  • 10.2.1. AstraZeneca PLC
    • 10.2.1.1. Key Information
    • 10.2.1.2. Overview
    • 10.2.1.3. Financial (Subject to Data Availability)
    • 10.2.1.4. Product Summary
    • 10.2.1.5. Recent Developments
  • 10.2.2. Boehringer Ingelheim GmbH
  • 10.2.3. GlaxoSmithKline plc
  • 10.2.4. Novartis AG
  • 10.2.5. Koninklijke Philips N.V.
  • 10.2.6. 3M company
  • 10.2.7. Janssen (Johnson & Johnson)
  • 10.2.8. Clement Clarke International
  • 10.2.9. Briggs Healthcare
  • 10.2.10. Aerogen

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption